Copyright
©The Author(s) 2017.
World J Gastrointest Endosc. Apr 16, 2017; 9(4): 171-176
Published online Apr 16, 2017. doi: 10.4253/wjge.v9.i4.171
Published online Apr 16, 2017. doi: 10.4253/wjge.v9.i4.171
Table 1 Complications of sphincterotomy and risk factors for hemorrhage
| Complications of sphincterotomy | Risk factors for hemorrhage |
| Pancreatitis - 1.0%-15.7% (Most common complication) | Presence of coagulopathy |
| Hemorrhage - 2%-7% | Use of anti-coagulation |
| Cholangitis - 1% - (Fever, chills, elevated liver enzymes, and/or positive blood culture within 48 h after the procedure) | Cholangitis |
| Cholecystitis - (Clinical and radiographic evidence of an inflamed gallbladder) | Low endoscopist case volume |
Table 2 Bleeding grading system
| Mild | Moderate | Severe |
| Transfusion is not required, with evidence of bleeding | Transfusion of 4 units or less is required | Transfusion of 5 units or more is required |
| Hemoglobin drop of less than 3 g/dL | No surgical intervention | Angiographic or surgical intervention |
| Immediate bleeding - seen in 30% patients (8) - endoscopic venous oozing which stopped with epinephrine | ||
| Delayed bleeding - occur up to 2 wk after the procedure - hematemesis, melena, haematochezia | ||
| Severe bleeding - 0.1%-0.5% | ||
Table 3 Serotonin reuptake inhibitors medications included in the study
| Serotonin reuptake inhibitors | Serotonin-norepinephrine reuptake inhibitors |
| Citalopram (Celexa) | Desvenlafaxine (Pristiq) |
| Escitalopram (Lexapro, Cipralex) | Duloxetine (Cymbalta) |
| Paroxetine (Paxil, Seroxat) | Levomilnacipran (Fetzima) |
| Fluoxetine (Prozac) | Milnacipran (Ixel, savella) |
| Fluvoxamine (Luvox) | Tofenacin (Elamol, tofacine) |
| Sertraline (Zoloft, lustral) | Venlafaxine (Effexor) |
Table 4 Patient demographics n (%)
| Factor | Overall (n = 447) | SRI (n = 219) | No SRI (n = 228) | P value | |||
| n | Summary | n | Summary | n | Summary | ||
| Age (yr) | 445 | 64.4 ± 17.9 | 219 | 64.0 ± 16.8 | 226 | 64.7 ± 19.0 | 0.681 |
| Male | 447 | 112 (25.1) | 219 | 47 (21.5) | 228 | 65 (28.5) | 0.0863 |
| BMI | 442 | 29.5 ± 7.5 | 218 | 29.7 ± 7.6 | 224 | 29.3 ± 7.4 | 0.591 |
| Smoking | 435 | 216 (49.7) | 216 | 114 (52.8) | 219 | 102 (46.6) | 0.203 |
| Alcohol use | 432 | 161 (37.3) | 215 | 69 (32.1) | 217 | 92 (42.4) | 0.0273 |
| Cardiovascular disorder | 447 | 111 (24.8) | 219 | 53 (24.2) | 228 | 58 (25.4) | 0.763 |
| Depression | 445 | 160 (36.0) | 219 | 99 (45.2) | 226 | 61 (27.0) | < 0.0013 |
| Renal disease | 447 | 55 (12.3) | 219 | 30 (13.7) | 228 | 25 (11.0) | 0.383 |
| Intestinal disease | 447 | 66 (14.8) | 219 | 29 (13.2) | 228 | 37 (16.2) | 0.373 |
| History of UGI bleed | 389 | 1 (0.26) | 207 | 0 (0.0) | 182 | 1 (0.55) | 0.474 |
Table 5 Patients lab values
| Factor | Overall (n = 447) | SRI (n = 219) | No SRI (n = 228) | P value | |||
| n | Summary | n | Summary | n | Summary | ||
| PPI | 447 | 111 (24.8) | 219 | 51 (23.3) | 228 | 60 (26.3) | 0.462 |
| Platelets | 435 | 213 | 222 | 0.591 | |||
| 140-400 | 432 (99.3) | 212 (99.5) | 220 (99.1) | ||||
| > 400 | 3 (0.69) | 1 (0.47) | 2 (0.90) | ||||
| INR | 391 | 190 | 201 | - | |||
| 0.9-1.2 | 391 (100.0) | 190 (100.0) | 201 (100.0) | ||||
| PTT | 361 | 171 | 190 | - | |||
| 24.7-32.7 s | 361 (100.0) | 171 (100.0) | 190 (100.0) | ||||
Table 6 Number of endoscopic retrograde cholangiopancreatography
| Number of ERCPs | Overall (n = 447) | SRI (n = 219 ) | No SRI (n = 228) | P value |
| 1 | 432 (96.6) | 214 (97.7) | 218 (95.6) | 0.231 |
| 2 | 13 (2.9) | 3 (1.4) | 10 (4.4) | |
| 3 | 2 (0.45) | 2 (0.91) | 0 (0.0) |
Table 7 Indications for endoscopic retrograde cholangiopancreatography
| Overall (n = 447) | SRI (n = 219) | No SRI (n = 228) | P value | ||
| Summary | n (%) | n (%) | |||
| Abnormal CT | 16 (3.8) | 9 (4.3) | 7 (3.3) | 0.571 | |
| Abdominal pain | 90 (21.2) | 43 (20.6) | 47 ( 21.9) | 0.751 | |
| Abnormal LFT | 62 (14.6) | 32 (15.3) | 30 (14.0) | 0.691 | |
| Biliary dilation | 8 (1.9) | 6 (2.9) | 2 (0.93) | 0.172 | |
| Bile duct stones | 187 (44.1) | 96 (45.9) | 91 (42.3) | 0.451 | |
| Complications of prior biliary surgery | 6 (1.4) | 4 (1.9) | 2 (0.93) | 0.442 | |
| Jaundice | 49 (11.6) | 16 (7.7) | 33 (15.3) | 0.0131 | |
| Cholangitis | 9 (2.1) | 209 | 4 (1.9) | 5 (2.3) | 0.992 |
Table 8 Bleeding and management
- Citation: Yadav D, Vargo J, Lopez R, Chahal P. Does serotonin reuptake inhibitor therapy increase the risk of post-sphincterotomy bleeding in patients undergoing endoscopic retrograde cholangio-pancreatography? World J Gastrointest Endosc 2017; 9(4): 171-176
- URL: https://www.wjgnet.com/1948-5190/full/v9/i4/171.htm
- DOI: https://dx.doi.org/10.4253/wjge.v9.i4.171
